Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Capital Expenditures (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Capital Expenditures for 6 consecutive years, with $106000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 66.56% to $106000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 190.53% year-over-year, with the annual reading at $1.0 million for FY2025, 190.53% up from the prior year.
  • Capital Expenditures for Q4 2025 was $106000.0 at Janux Therapeutics, up from $93000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $5.3 million in Q4 2022, with the low at -$1.2 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $473050.0, with a median of $261000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures surged 62800.0% in 2021, then crashed 12600.0% in 2022.
  • Over 5 years, Capital Expenditures stood at $629000.0 in 2021, then surged by 735.61% to $5.3 million in 2022, then crashed by 122.89% to -$1.2 million in 2023, then surged by 126.35% to $317000.0 in 2024, then crashed by 66.56% to $106000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $106000.0, $93000.0, and $607000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.